Interpretation of Liver Function Panel in Patients with Newly Found Liver Lesions

Key Findings and Clinical Significance

The American Gastroenterological Association suggests that low albumin levels (less than 3.5 g/dL) are the most concerning finding, as albumin is produced exclusively by the liver and reflects hepatic synthetic capacity 1, 2
The European Association for the Study of the Liver notes that low total protein levels (less than 6.4 g/dL) compound this concern, and albumin concentrations are reduced in many non-hepatic conditions, including sepsis, systemic inflammatory disorders, nephrotic syndrome, malabsorption, and gastrointestinal protein loss 1, 2
The American College of Radiology recommends that overinterpretation of albumin as a marker of liver disease severity is not always merited, as it can be low in multiple clinical situations unrelated to hepatic dysfunction 1

The American Association for the Study of Liver Diseases states that a total bilirubin level within the normal range (less than 1.2 mg/dL) with only minimally elevated direct bilirubin (less than 0.18 mg/dL) argues against significant cholestatic disease or biliary obstruction 2
The National Institute of Diabetes and Digestive and Kidney Diseases notes that direct bilirubin represents a percentage of total bilirubin, which is within the expected range for normal individuals, and the indirect (unconjugated) bilirubin is normal, ruling out hemolysis or Gilbert's syndrome as contributors 3, 4

The American College of Radiology suggests that ALT and AST levels at the lower end of normal or slightly below normal are inconsistent with active hepatocellular injury, which would elevate aminotransferases 5, 6
The European Association for the Study of the Liver notes that very low aminotransferases in the context of a liver lesion may suggest chronic, stable liver disease without active inflammation, non-hepatic cause of hypoalbuminemia, or possible loss of hepatocyte mass 1, 5

The American Gastroenterological Association recommends that non-hepatic causes of hypoalbuminemia, such as nephrotic syndrome, protein-losing enteropathy, malnutrition or malabsorption, systemic inflammatory state, and sepsis, should be investigated first given the lack of other liver injury markers 1, 2
The American College of Radiology suggests that chronic stable liver disease with impaired synthetic function but no active inflammation, and space-occupying lesion without significant hepatocellular dysfunction, are also possible considerations 1, 5

The American Association for the Study of Liver Diseases recommends immediate laboratory evaluation, including prothrombin time (PT) and INR to assess clotting factor synthesis, complete metabolic panel, urinalysis, and platelet count 1, 2
The European Association for the Study of the Liver suggests clinical assessment, including evaluation for signs of chronic liver disease, assessment of nutritional status and gastrointestinal symptoms, and review for systemic inflammatory conditions or recent infections 1
The American College of Radiology recommends imaging follow-up, including characterization of the liver lesion with contrast-enhanced CT or MRI, and assessment for signs of portal hypertension if chronic liver disease is suspected 5, 6

The American Association for the Study of Liver Diseases recommends that albumin and bilirubin be used together to assess liver function, as they reflect different aspects of liver function, with albumin indicating hepatic synthetic capacity and bilirubin indicating hepatic excretory function 7, 8

The European Association for the Study of the Liver suggests that the ALBI score, which combines albumin and bilirubin, can be used to stratify patients with liver disease into different prognostic groups, with median survivals of 26 months for ALBI grade 1 and 14 months for ALBI grade 2 9, 10
The American College of Gastroenterology recommends that elevated bilirubin be used as a predictor of poor outcomes, including tumor recurrence after resection, drop-out from transplant waiting lists, and reduced survival in advanced HCC 11

The National Comprehensive Cancer Network recommends that patients with newly identified liver lesions and abnormal liver function tests undergo a clinical decision-making algorithm, which includes calculating the Child-Pugh score and ALBI grade for prognostic stratification, and assessing for signs of portal hypertension 7, 8, 9, 11
The American Association for the Study of Liver Diseases suggests that patients with both albumin and bilirubin abnormalities undergo further evaluation, including assessment for signs of portal hypertension and consideration of the MELD score if transplant evaluation is relevant 7, 8, 9, 10